Skip to main content
Search
Search
Quick Search anywhere
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Quick Search in Journals
Skip main navigation
JACC Journals › JACC: CardioOncology › Archives
Next
September 1, 2019

JACC: CardioOnc | Vol. 1 No. 1

ORIGINAL RESEARCH

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I TrialOpen Access

Original Research
  • Darryl P. Leong,
  • Sukhbinder Dhesy-Thind,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 1–10.

Trastuzumab Cures Cancer and Disrupts the Practice of CardiologyOpen Access

Editorial Comment
  • Richard M. Steingart,
  • Chau T. Dang,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 11–13.

Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition

Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor InhibitionOpen Access

Original Research
  • Wendy J. Bottinor,
  • Evan L. Brittain,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 14–23.

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor

Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth FactorOpen Access

Original Research
  • Sarah Waliany,
  • Ronald M. Witteles,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 24–36.

Hypertension and Antiangiogenesis: The Janus Face of VEGF Inhibitors Open Access

Editorial Comment
  • Rhian M. Touyz and
  • Ninian N. Lang

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 37–40.

Pre-Diagnosis Exercise and Cardiovascular Events in Primary Breast Cancer: Women’s Health Initiative

Pre-Diagnosis Exercise and Cardiovascular Events in Primary Breast Cancer: Women’s Health InitiativeOpen Access

Original Research
  • Tochi M. Okwuosa,
  • Lee W. Jones,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 41–50.

Exercise and Cardiovascular Outcomes in Older Women With Breast Cancer: The Heart of the Matter Open Access

Editorial Comment
  • Lindsay L. Peterson and
  • Jennifer A. Ligibel

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 51–53.

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing ChemotherapyOpen Access

Original Research
  • Muthiah Vaduganathan,
  • Ambarish Pandey,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 54–65.

Cardioprotection From Cardiotoxicity: The Quest for the Holy Grail Goes On Open Access

Editorial Comment
  • Guilherme H. Oliveira

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 66–67.

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast CancerOpen Access

Original Research
  • Ariane V.S. Macedo,
  • Antonio L.P. Ribeiro,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 68–79.

Overcoming Inertia to Tame the Red DevilOpen Access

Editorial Comment
  • Christine E. Simmons

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 80–83.

Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular Protection

Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular ProtectionOpen Access

Original Research
  • Adeline Gasser,
  • Canan G. Nebigil,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 84–102.

Prokineticin-izing Doxorubicin-Damaged HeartsOpen Access

Editorial Comment
  • Emilio Hirsch

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 103–104.

STATE-OF-THE-ART REVIEWS

The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity

The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular ToxicityOpen Access

State-of-the-Art Review
  • Lori M. Minasian,
  • Bonnie Ky,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 105–113.

Birth and Maturation of Cardio-Oncology

Birth and Maturation of Cardio-OncologyOpen Access

Viewpoint
  • Deepak L. Bhatt

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 114–116.

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and ManagementOpen Access

State-of-the-Art Review
  • Ronald M. Witteles and
  • Michaela Liedtke

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 117–130.

EDITOR'S PAGE

JACC: CardioOncology: Poised to Serve a Maturing, Collaborative Field

JACC: CardioOncology: Poised to Serve a Maturing, Collaborative FieldOpen Access

Editor's Page
  • Bonnie Ky

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 131–132.

LEADERSHIP PAGE

Cardio-Oncology: Stronger Together

Cardio-Oncology: Stronger TogetherOpen Access

Leadership Page
  • Richard J. Kovacs and
  • Howard A. Burris

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 133–134.

RESEARCH LETTERS

Incidental Coronary Artery Calcification in Cancer Imaging

Incidental Coronary Artery Calcification in Cancer ImagingOpen Access

Research Letter
  • Sarah Cuddy,
  • John D. Groarke,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 135–137.

Current Management of Symptomatic Pericardial Effusions in Cancer Patients

Current Management of Symptomatic Pericardial Effusions in Cancer PatientsOpen Access

Research Letter
  • Audrey Besnard,
  • Nicolas Amabile,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 137–140.

CLINICAL CASE CHALLENGES

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic ShockOpen Access

Clinical Case Challenges
  • Osnat Itzhaki Ben Zadok,
  • Tuvia Ben Gal,
  • et. al.

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) 141–144.

Full Issue PDFOpen Access

J Am Coll Cardiol CardioOnc. 2019 Sep, 1 (1) I–CXLVII.